Background: Galectin-9 is involved in chemotaxis and adhesion of eosinophils, and is induced in vascular endothelial cells by interferon-γ (IFN-γ). 15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is a ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ), and known to modulate the expression of various genes. Methods: We have studied the effect of 15d-PGJ2 on the IFN-γ-induced galectin-9 expression in human umbilical vein endothelial cells (HUVEC) in culture. Results: 15d-PGJ2 inhibited the IFN-γ-induced galectin-9 expression in a PPAR-γ-independent manner, and also inhibited the adhesion of EoL-1 cells to an HUVEC monolayer treated with IFN-γ. 15d-PGJ2 partially inhibited IFN-γ-induced phosphorylation of STAT-1 in HUVEC. Conclusions: 15d-PGJ2 may regulate inflammatory reactions through the inhibition of galectin-9 expression.

Keywords:
15-Deoxy-Δ12,14-prostaglandin J2, IFN-=γ, Galectin-9, Endothelial cells
1.
Hirabayashi J, Kasai K: The family of metazoan metal-independent beta-galactoside-binding lectins: Structure, function and molecular evolution. Glycobiology 1993;3:297–304.
2.
Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M: Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 1998;273:16976–16984.
3.
Hirashima M: Ecalectin as a T cell-derived eosinophil chemoattractant. Int Arch Allergy Immunol 1999;120(suppl 1):7–10.
4.
Hirashima M: Ecalectin/galectin-9, a novel eosinophil chemoattractant: Its function and production. Int Arch Allergy Immunol 2000;122(suppl 1):6–9.
5.
Imaizumi T, Kumagai M, Sasaki N, Kurotaki H, Mori F, Seki M, Nishi N, Fujimoto K, Tanji K, Shibata T, Tamo W, Matsumiya TK, Yoshida H, Cui X-F, Takanashi S, Hanada K, Okumura K, Yagihashi S, Wakabayashi K, Nakamura T, Hirashima M, Satoh K: Interferon-γ stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukocyte Biol 2002;72:486–491.
6.
Yoshida H, Imaizumi T, Kumagai M, Kimura K, Satoh C, Hanada N, Fujimoto K, Nishi N, Tanji K, Matsumiya T, Mori F, Cui XF, Tamo W, Shibata T, Takanashi S, Okumura K, Nakamura T, Wakabayashi K, Hirashima M, Sato Y, Satoh K: Interleukin-1β stimulates galectin-9 expression in human astrocytes. Neuroreport 2001;12:3755–3758.
7.
Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 2000;405:421–424.
8.
Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994;79:1147–1156.
9.
Vamercq J, Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141–148.
10.
Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995;83:803–812.
11.
Kliewer SA, Lenhard JM, Wilson TM, Patel I, Morris DC, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995;83:813–819.
12.
Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD: Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000;164:6503–6508.
13.
Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL: Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999;19:2094–2104.
14.
Chen NG, Han X: Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. Biochem Biophys Res Commun 2001;282:717–723.
15.
Zimmerman GA, Whatley RE, McIntyre TM, Benson DE, Prescott SM: Endothelial cells for studies of platelet-activating factor and arachidonate metabolites. Methods Enzymol 1990;187:520–535.
16.
Imaizumi T, Matsumiya T, Fujimoto K, Okamoto K, Cui X, Ohtaki U, Yoshida H, Satoh K: Interferon-γ stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells. Tohoku J Exp Med 2000;192:127–139.
17.
Imaizumi T, Aratani S, Nakajima T, Carlson M, Matsumiya T, Tanji K, Ookawa K, Yoshida H, Tsuchida S, McIntyre TM, Prescott SM, Zimmerman GA, Satoh K: Retinoic acid-inducible gene-I is induced in endothelial cells by LPS and regulates expression of COX-2. Biochem Biophys Res Commun 2002;292:274–279.
18.
Jung EY, Ohshima Y, Shintaku N, Sumimoto S, Heike T, Katamura K, Mayumi M: Effects of cyclic AMP on expression of LFA-1, Mac-1, and VLA-4 and eosinophilic differentiation of a human leukemia cell line, EoL-1. Eur J Haematol 1994;53:156–162.
19.
Yamazaki R, Hatano H, Aiyama R, Matsuzaki T, Hashimoto S, Yokokura T: Diarylheptanoids suppress expression of leukocyte adhesion molecules on human vascular endothelial cells. Eur J Pharmacol 2000;404:375–385.
20.
Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferate-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998;391:79–82.
21.
Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82–86.
22.
Tsubouchi Y, Kawahito Y, Kohno M, Inoue K, Hla T, Sano H: Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Δ12,14-prostaglandin J2. Biochem Biophys Res Commun 2001;283:750–755.
23.
Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM: PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48–52.
24.
Jozkowicz A, Dulak J, Prager M, Nanobashvili J, Nigisch A, Winter B, Weigel G, Huk I: Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-γ-independent manner. Prostaglandins Other Lipid Mediat 2001;66:165–177.
25.
Decker T, Kovarik P, Meinke A: GAS elements: A few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 1997;17:121–134.
26.
Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS: Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J Clin Invest 1997;99:2452–2461.
27.
Suk K, Hwang DY, Lee MS: Natural autoantibody to galectin-9 in normal human sera. J Clin Immunol 1999;19:158–165.
28.
Lipkowitz MS, Leal-Pinto E, Rappoport JZ, Najfeld V, Abramson RG: Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 2001;107:1103–1115.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.